Litigation
Celgene Corp. v. Natco Pharma Ltd. et al.
settled2:10-cv-05197
Auto-generating section 1 of 5: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
- Filed
- 2010-10-08
- Terminated
- 2016-01-05
Patents at issue (1)
Plaintiffs (1)
Summary
Celgene brought this ANDA patent-infringement suit against Natco, Arrow, and Watson. The '717 patent was added by Fifth Amended Complaint on May 6, 2013, and the case settled on December 22, 2015, with a license to market generic lenalidomide beginning January 31, 2026; the docket terminated January 5, 2016.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
In the news
What the press has reported about this case, summarized with links to the source articles.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).